Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer ...

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic ...

Anorectal malignant melanoma (AMM) is a rare disease with a poor prognosis, accounting for 10 years), as in the present case, are rare. The patient was an 80-year-old woman who underwent laparoscopic ...

Cardiff Oncology has sufficient funds to operate until early 2027 but will face funding challenges by 2026. Learn why CRDF ...

has been given accelerated approval by the FDA as first-line therapy for BRAF V600E-mutated metastatic colorectal cancer, one of a series of new cancer indications that the company reckons will ...

Based on data from the phase 3 CheckMate-8HW trial, the combination of nivolumab and ipilimumab has been approved by the FDA in metastatic colorectal cancer. A phase 2 trial will evaluate leronlimab’s ...

Conclusions These results illustrate the importance of RNF43, along with BRAF mutation in the serrated neoplasia pathway (both the sporadic and familial forms), inform genetic diagnosis protocol and ...